Spero Therapeutics (SPRO) Accounts Payables (2016 - 2026)

Spero Therapeutics (SPRO) has 11 years of Accounts Payables data on file, last reported at $217000.0 in Q1 2026.

• Quarterly Accounts Payables fell 87.71% year-over-year to $217000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $217000.0 (down 87.71% YoY) and the FY2025 annual result came in at $693000.0, down 90.51% from the prior year.
• Accounts Payables fell to $217000.0 in Q1 2026, from $693000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $7.3 million in Q4 2024 to a low of $217000.0 in Q1 2026.
• A 5-year average of $2.2 million and a median of $1.4 million in 2025 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables surged 452.13% — and 2025, when it sank 90.51%.
• Tracing SPRO's Accounts Payables over 5 years: stood at $617000.0 in 2022, then soared by 123.34% to $1.4 million in 2023, then jumped by 430.19% to $7.3 million in 2024, then sank by 90.51% to $693000.0 in 2025, then sank by 68.69% to $217000.0 in 2026.
• The last three Accounts Payables figures came in at $217000.0 (Q1 2026), $693000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.